NASDAQ:FGENFibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FGEN shares have increased by 18.1% and is now trading at $41.82. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.50. The biopharmaceutical company had revenue of $24.40 million for the quarter, compared to analysts' expectations of $72.58 million. FibroGen had a negative net margin of 42.75% and a negative return on equity of 19.32%. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.53) earnings per share. View FibroGen's earnings history.

5 brokers have issued 12-month target prices for FibroGen's stock. Their forecasts range from $40.00 to $80.00. On average, they expect FibroGen's stock price to reach $57.60 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price. View analysts' price targets for FibroGen.

News stories about FGEN stock have trended negative on Friday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. FibroGen earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about FibroGen.

Some companies that are related to FibroGen include GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), ACADIA Pharmaceuticals (ACAD), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.03%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff, and Thomas F Kearns Jr. View insider buying and selling activity for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $41.82.

FibroGen has a market capitalization of $3.73 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]